利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.025 秒)

    ACCELERATION SENSOR CHIP PACKAGE
    3.
    发明申请
    ACCELERATION SENSOR CHIP PACKAGE 有权
    加速传感器芯片包装

    公开(公告)号：US20100043553A1

    公开(公告)日：2010-02-25

    申请号：US12607407

    申请日：2009-10-28

    申请人： Shunji ICHIKAWA

    发明人： Shunji ICHIKAWA

    IPC分类号： G01P15/12

    CPC分类号： G01P1/023 ,  G01P15/123 ,  H01L2224/48091 ,  H01L2224/48465 ,  H01L2224/49175 ,  H01L2224/73265 ,  H01L2924/10253 ,  H01L2924/1461 ,  H01L2924/00014 ,  H01L2924/00

    摘要： An acceleration sensor chip package includes an acceleration sensor chip; a sensor control chip; a re-wiring layer; an outer terminal; a sealing portion; and a substrate. The acceleration sensor chip includes a frame portion; a movable structure; a detection element; and an electrode pad electrically. The re-wiring layer has a wiring portion connected to the electrode pad. The electrode pad is electrically connected to a conductive bump. The sensor control chip has a sensor control electrode pad electrically connected to the conductive bump. The outer terminal is connected to the wiring portion and disposed in the outer region. The sealing portion seals the sensor control chip, the electrode pad, and the re-wiring layer, so that the movable structure is movable. The substrate is attached to the acceleration sensor chip to seal an opening portion.

    摘要翻译： 加速度传感器芯片封装包括加速度传感器芯片; 传感器控制芯片; 重新布线层; 外部终端; 密封部分; 和基材。 加速度传感器芯片包括框架部分; 可移动结构; 检测元件; 和电极垫。 再布线层具有连接到电极焊盘的布线部分。 电极焊盘电连接到导电凸块。 传感器控制芯片具有电连接到导电凸块的传感器控制电极焊盘。 外部端子连接到布线部分并且设置在外部区域中。 密封部密封传感器控制芯片，电极焊盘和再布线层，使得可移动结构是可移动的。 衬底附接到加速度传感器芯片以密封开口部分。

    Method for manufacturing printed wiring board
    4.
    发明申请
    Method for manufacturing printed wiring board 审中-公开
    印刷电路板制造方法

    公开(公告)号：US20060236534A1

    公开(公告)日：2006-10-26

    申请号：US11406298

    申请日：2006-04-19

    申请人： Shunji Ichikawa

    发明人： Shunji Ichikawa

    IPC分类号： H05K3/36

    CPC分类号： H05K3/403 ,  H05K3/0052 ,  H05K3/0094 ,  H05K3/064 ,  H05K3/243 ,  H05K3/28 ,  H05K3/4046 ,  H05K3/427 ,  H05K2201/09181 ,  H05K2201/0959 ,  H05K2201/10386 ,  H05K2203/0574 ,  H05K2203/1394 ,  Y10T29/49126 ,  Y10T29/49128 ,  Y10T29/49155 ,  Y10T29/49165

    摘要： A method for manufacturing a printed wiring board comprises the steps of defining contact holes for forming both via holes forming through holes and contact terminals, in an insulated board with conductor layers formed over obverse and reverse surfaces thereof; forming conductive layers in inner peripheral surfaces of the via holes and the contact holes; forming etching masks for covering regions for forming wiring patterns and the through holes, over the obverse and reverse conductor layers, and etching the insulated board to remove the exposed conductor layers and the conductive layers formed over the inner peripheral surfaces of the exposed contact holes; and forming contact terminals for electrically connecting the obverse and reverse wiring patterns in the inner peripheral surfaces of the contact holes respectively.

    摘要翻译： 一种制造印刷电路板的方法包括以下步骤：在绝缘板上形成用于形成通孔和接触端子的通孔，用于形成在其正面和反面上形成有导体层的绝缘板; 在所述通孔和所述接触孔的内周面中形成导电层; 在正面和反面导体层上形成用于形成布线图案和通孔的覆盖区域的蚀刻掩模，并蚀刻绝缘板以去除暴露的导体层和形成在暴露的接触孔的内周表面上的导电层; 以及形成用于将接触孔的内周面中的正面和反向布线图案电连接的接触端子。

    Therapeutic agent for Parkinson's disease
    5.
    发明授权
    Therapeutic agent for Parkinson's disease 失效
    帕金森病治疗剂

    公开(公告)号：US5484920A

    公开(公告)日：1996-01-16

    申请号：US133510

    申请日：1993-10-07

    申请人： Fumio Suzuki ,  Junichi Shimada ,  Nobuaki Koike ,  Joji Nakamura ,  Shizuo Shioazaki ,  Shunji Ichikawa ,  Akio Ishii ,  Hiromi Nonaka

    发明人： Fumio Suzuki ,  Junichi Shimada ,  Nobuaki Koike ,  Joji Nakamura ,  Shizuo Shioazaki ,  Shunji Ichikawa ,  Akio Ishii ,  Hiromi Nonaka

    IPC分类号： C07D473/06 ,  C07D473/08 ,  C07D473/12 ,  A61K31/52

    CPC分类号： C07D473/08 ,  C07D473/06 ,  C07D473/12

    摘要： Agents for the treatment of Parkinson's disease contain, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: ##STR1## in which R.sup.1, R.sup.2 are R.sup.3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R.sup.4 represents cycloalkyl, --(CH.sub.2).sub.n --R.sup.5 (in which R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or ##STR2## in which Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen, or lower alkyl; and Z represents substituted or unsubstituted aryl, ##STR3## in which R.sup.6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X.sup.1 and X.sup.2 represent independently O or S.

    摘要翻译： 用于治疗帕金森病的药物含有作为活性成分的黄嘌呤衍生物或其药学上可接受的盐。 黄嘌呤衍生物由下式表示：其中R 1，R 2为R 3独立地为氢，低级烷基，低级烯基或低级炔基; 并且R 4表示环烷基， - （CH 2）n -R 5（其中R 5表示取代或未取代的芳基或取代或未取代的杂环基; n为0至4的整数）或其中Y 1和Y 2表示 独立地是氢，卤素或低级烷基; Z表示取代或未取代的芳基，其中R 6表示氢，羟基，低级烷基，低级烷氧基，卤素，硝基或氨基; m表示1〜4的整数，或取代或未取代的杂环基; X1和X2独立地表示O或S.

    Therapeutic and/or preventive agents for a sleep disorder
    9.
    发明授权
    Therapeutic and/or preventive agents for a sleep disorder 有权
    用于睡眠障碍的治疗和/或预防剂

    公开(公告)号：US07928098B2

    公开(公告)日：2011-04-19

    申请号：US11997585

    申请日：2006-08-02

    申请人： Noriaki Uesaka ,  Shunji Ichikawa ,  Takao Nakajima

    发明人： Noriaki Uesaka ,  Shunji Ichikawa ,  Takao Nakajima

    IPC分类号： A61K31/555 ,  A61K31/54 ,  A61K31/535 ,  A61K31/4965 ,  A61K31/44 ,  A61K31/425

    CPC分类号： C07D417/14 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  A61K31/5377

    摘要： The present invention provides a therapeutic and/or preventive agent for a sleep disorder comprising, as an active ingredient, a thiazole derivative represented by the general formula (I), [wherein R1 represents a five-membered aromatic heterocyclic group including at least one oxygen atom, or the like, R2 represents halogen or the like, and R3 represents —NR10R11 (wherein R10 and R11 may be the same or different, and each represents a hydrogen atom or the like), or the like] or a pharmaceutically acceptable salt thereof.

    摘要翻译： 本发明提供了一种睡眠障碍的治疗和/或预防剂，其包含作为活性成分的由通式（I）表示的噻唑衍生物，其中R 1表示包含至少一个氧的五元芳族杂环基 原子等，R 2表示卤素等，R 3表示-NR 10 R 11（其中R 10和R 11可以相同或不同，各自表示氢原子等）或其药学上可接受的盐 其中。

    Xanthine derivatives
    10.
    发明授权
    Xanthine derivatives 失效
    黄嘌呤衍生物

    公开(公告)号：US5703085A

    公开(公告)日：1997-12-30

    申请号：US537770

    申请日：1995-10-20

    申请人： Fumio Suzuki ,  Nobuaki Koike ,  Junichi Shimada ,  Joji Nakamura ,  Shizuo Shiozaki ,  Shigeto Kitamura ,  Shunji Ichikawa ,  Hiroshi Kase ,  Hiromi Nonaka

    发明人： Fumio Suzuki ,  Nobuaki Koike ,  Junichi Shimada ,  Joji Nakamura ,  Shizuo Shiozaki ,  Shigeto Kitamura ,  Shunji Ichikawa ,  Hiroshi Kase ,  Hiromi Nonaka

    IPC分类号： C07D473/06 ,  A61K31/52 ,  C07D473/10 ,  C07D473/12

    CPC分类号： C07D473/06

    摘要： The present invention relates to novel xanthine derivatives and pharmaceutically acceptable salts thereof, represented by Formula (I): ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 independently represent hydrogen, lower alkyl, lower alkenyl, or lower alkynyl, R.sup.4 represents lower alkyl, or substituted or unsubstituted aryl, R.sup.5 and R.sup.6 independently represent hydrogen, lower alkyl, and lower alkoxy, or R.sup.5 and R.sup.6 are combined together to represent --O--(CH.sub.2)p--O-- (p is an integer of 1 to 3), n represents 0, 1, or 2, and m represents 1 or 2. The compounds of the present invention have an adenosine A.sub.2 receptor antagonistic activity, and are useful for the treatment or prevention of various kinds of diseases caused by hyperergasia of adenosine A.sub.2 receptors (for example, Parkinson's disease, senile dementia, depression, asthma, and osteoporosis).

    摘要翻译： PCT No.PCT / JP95 / 00267 Sec。 371 1995年10月20日第 102（e）1995年10月20日日期PCT提交1995年2月23日PCT公布。 公开号WO95 / 23148 日期：1995年8月31日本发明涉及由式（I）表示的新颖的黄嘌呤衍生物及其药学上可接受的盐：其中R1，R2和R3独立地表示氢，低级烷基，低级链烯基或 低级炔基，R 4表示低级烷基或取代或未取代的芳基，R 5和R 6独立地表示氢，低级烷基和低级烷氧基，或者R 5和R 6结合在一起代表-O-（CH 2）p O-（p是整数 1〜3），n表示0,1或2，m表示1或2.本发明化合物具有腺苷A2受体拮抗活性，可用于治疗或预防各种疾病 腺苷A2受体（例如帕金森病，老年性痴呆，抑郁症，哮喘和骨质疏松症）的过度高血症。